지니너스

389030KOSDAQ

50.6 / 100

Reference Date: 2026-09-08

Financial Score15.0 / 40

News Sentiment19.6 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 20.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Geninus focuses on genomics, bioinformatics, and the development of in-vitro diagnostic medical devices, leveraging advanced technologies such as NGS and PCR to provide innovative healthcare solutions in early cancer detection, liquid biopsy, and precision medicine. The company also conducts research on mutations and biomarkers to support disease prognosis prediction and personalized treatment strategies.

Number of Employees

59people

Average Salary

72.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

7.49Industry Average 1.200.0Point

6.2x industry avg (risky)

ROE

-110.87Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

18.72Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲27.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼8.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -59.7% (declining, 3yr)

Detailed News Sentiment

7 totalPositive 6Neutral 1Negative 0Average Sentiment Score 78.6

Positive
신약 실패 줄이는 '멀티모달'
지니너스의 멀티모달 분석 플랫폼 고도화로 신약 개발 성공률 향상 기대.
Positive
지니너스 사업 피봇팅…'한국 카토그래피' 될까
지니너스는 AI 기반 신약 타겟 발굴 플랫폼을 통해 사업 영역을 확장하고 글로벌 시장 진출을 모색하며 긍정적인 변화를 추구하고 있다.
Neutral
[의료계 소식]암세포 둘러싼 ‘둥지’까지 공격… 새 방사성 치료법 .....
The news focuses on advancements in medical technology unrelated to specific stock performance.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 1,730Won52-week high 6,27052-week low 1,627

1-month return0.0Point

1m -20.28% (strong drop)

Volume trend5.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14